26 January 2012 - US Trius Therapeutics Inc (NASADAQ:TSRX) said on Wednesday it intends to sell common shares in an underwritten public offering.

The company has hired Citigroup (NYSE:C) and Piper Jaffray & Co as joint book-running managers of the transaction.

The offering, including timing, size and pricing, depends on market conditions and may not proceed if the market is not receptive.

The securities will be offered by the company within an effective shelf registration.

Trius Therapeutics discovers, develops and commercialises new antibiotics for life-threatening infections. The company's key investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase III clinical trial for the treatment of acute bacterial skin and skin structure infections.